Analyst’s Keeping an Eye on Monsanto Company (NYSE:MON)

Analysts are weighing in on how Monsanto Company (NYSE:MON), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.5. The stock is rated as buy by 7 analysts, with 3 outperform and 8 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 17.00 analysts offering adjusted EPS forecast have a consensus estimate of $2.42 a share, which would compare with $2.39 in the same quarter last year. They have a high estimate of $2.73 and a low estimate of $2.16. Revenue for the period is expected to total nearly $4.50B from $4.58B the year-ago period.

For the full year, 19.00 Wall Street analysts forecast this company would deliver earnings of 4.63 per share, with a high estimate of $4.80 and a low estimate of $4.26. It had reported earnings per share of $5.73 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $13.69B versus 15.00B in the preceding year.

The analysts project the company to maintain annual growth of around 8.14% percent over the next five years as compared to an average growth rate of 14.87% percent expected for its competitors in the same industry.

Among the 15 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for MON is $104.80 but some analysts are projecting the price to go as high as $132.00. If the optimistic analysts are correct, that represents a 21 percent upside potential from the recent closing price of $109.15. Some sell-side analysts, particularly the bearish ones, have called for $80.00 price targets on shares of Monsanto Company (NYSE:MON).

In the last reported results, the company reported earnings of $2.39 per share, while analysts were calling for share earnings of $2.07. It was an earnings surprise of 15.50%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Monsanto Company, together with its subsidiaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces raw crop seeds, including corn, soybean, cotton, and canola seeds under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds, such as tomato, pepper, melon, cucumber, squash, beans, broccoli, onions, lettuce, and others under the Seminis and De Ruiter brands. It also develops biotechnology traits that assist farmers in controlling insects and weeds in corn, soybean, cotton, and canola crops under the SmartStax, YieldGard, YieldGard VT Triple, VT Triple PRO, and VT Double PRO brands; and Intacta RR2 PRO, and Bollgard and Bollgard II, as well as Roundup Ready and Roundup Ready 2 Yield, and Genuity brands. This segment also licenses a range of germplasm and trait technologies to large and small seed companies. The Agricultural Productivity segment manufactures and sells herbicides for agricultural, industrial, ornamental, turf, and residential lawn and garden applications for weed control, as well as for control of preemergent annual grass and small seeded broadleaf weeds in corn and other crops under the Roundup and Harness brands. The company markets its products through distributors, independent retailers and dealers, agricultural cooperatives, plant raisers, and agents, as well as directly to farmers. Monsanto Company has a collaborative agreement with Novozymes to discover, develop, and produce microbial solutions. The company was formerly known as Monsanto Ag Company and changed its name to Monsanto Company in March 2000. Monsanto Company was founded in 2000 and is headquartered in St. Louis, Missouri.

Analyst’s Ratings on CVS Health Corporation (NYSE:CVS)

Analysts are weighing in on how CVS Health Corp (NYSE:CVS), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.8. The stock is rated as buy by 12 analysts, with 10 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 24.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.30 a share, which would compare with $1.22 in the same quarter last year. They have a high estimate of $1.32 and a low estimate of $1.28. Revenue for the period is expected to total nearly $44.30B from $37.17B the year-ago period.

For the full year, 25.00 Wall Street analysts forecast this company would deliver earnings of 5.83 per share, with a high estimate of $5.90 and a low estimate of $5.79. It had reported earnings per share of $5.16 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $181.34B versus 153.29B in the preceding year.

The analysts project the company to maintain annual growth of around 14.93% percent over the next five years as compared to an average growth rate of 12.01% percent expected for its competitors in the same industry.

Among the 20 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CVS is $113.30 but some analysts are projecting the price to go as high as $123.00. If the optimistic analysts are correct, that represents a 31 percent upside potential from the recent closing price of $94.02. Some sell-side analysts, particularly the bearish ones, have called for $99.00 price targets on shares of CVS Health Corp (NYSE:CVS).

In the last reported results, the company reported earnings of $1.22 per share, while analysts were calling for share earnings of $1.20. It was an earnings surprise of 1.70%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

Analyst’s Ratings on Hanesbrands Incorporated (NYSE:HBI)

Analysts are weighing in on how Hanesbrands Inc. (NYSE:HBI), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.8. The stock is rated as buy by 7 analysts, with 6 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 9.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.52 a share, which would compare with $0.50 in the same quarter last year. They have a high estimate of $0.53 and a low estimate of $0.50. Revenue for the period is expected to total nearly $1.53B from $1.52B the year-ago period.

For the full year, 10.00 Wall Street analysts forecast this company would deliver earnings of 1.94 per share, with a high estimate of $1.97 and a low estimate of $1.92. It had reported earnings per share of $1.66 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $6.20B versus 5.73B in the preceding year.

The analysts project the company to maintain annual growth of around 11.00% percent over the next five years as compared to an average growth rate of 13.02% percent expected for its competitors in the same industry.

Among the 14 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for HBI is $36.36 but some analysts are projecting the price to go as high as $41.00. If the optimistic analysts are correct, that represents a 55 percent upside potential from the recent closing price of $26.47. Some sell-side analysts, particularly the bearish ones, have called for $29.00 price targets on shares of Hanesbrands Inc. (NYSE:HBI).

In the last reported results, the company reported earnings of $0.50 per share, while analysts were calling for share earnings of $0.50. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells various basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International. It sells bras, panties, shapewears, hosiery, mens underwear, childrens underwear, and socks; and other activewear, such as T-shirts, fleece, sport shirts, performance T-shirts and shorts, sports bras, and thermals, as well as licensed logo apparel in collegiate bookstores and other channels. The company licenses its Champion name for footwear and sports accessories. It provides its products primarily under the Maidenform, Bali, Playtex, Hanes, JMS/Just My Size, Lilyette, Wonderbra, Donna Karan, DKNY, Champion, Polo Ralph Lauren, L’eggs, Hanes Beefy-T, Gear for Sports, Duofold, DIM, Nur Die/Nur Der, Lovable, Shock Absorber, Abanderado, Zorba, Rinbros, Kendall, Sol y Oro, Fila, Bellinda, Edoo, and Track N Field brand names. The company markets its products through retailers, wholesalers, and third party embellishers, as well as directly to consumers. As of January 2, 2016, it operated 252 outlet stores in the United States; and Websites under the Hanes, One Hanes Place, JMS/Just My Size, Champion, and Maidenform names. The company also sells its products in Europe, Asia, Latin America, Canada, Australia, the Middle East, Africa, and the Caribbean. Hanesbrands Inc. was founded in 2005 and is headquartered in Winston-Salem, North Carolina.

Analyst’s Ratings on ImmunoGen, Incorporated (NASDAQ:IMGN)

Analysts are weighing in on how ImmunoGen, Inc. (NASDAQ:IMGN) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.3. The stock is rated as buy by 0 analysts, with 4 outperform and 5 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 9.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.39 a share, which would compare with $-0.35 in the same quarter last year. They have a high estimate of $-0.28 and a low estimate of $-0.42. Revenue for the period is expected to total nearly $16.86M from $12.61M the year-ago period.

For the full year, 10.00 Wall Street analysts forecast this company would deliver earnings of -1.54 per share, with a high estimate of $-1.42 and a low estimate of $-1.57. It had reported earnings per share of $-0.71 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $69.22M versus 85.54M in the preceding year.

Among the 8 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for IMGN is $10.44 but some analysts are projecting the price to go as high as $24.00. If the optimistic analysts are correct, that represents a 623 percent upside potential from the recent closing price of $3.32. Some sell-side analysts, particularly the bearish ones, have called for $5.00 price targets on shares of ImmunoGen, Inc. (NASDAQ:IMGN) .

In the last reported results, the company reported earnings of $-0.35 per share, while analysts were calling for share earnings of $-0.35. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. The companys clinical stage anticancer compounds include IMGN853 for the treatment of ovarian cancer, endometrial cancer, and other cancers, as well as IMGN529 and coltuximab ravtansine for the treatment of diffuse large B-cell lymphoma and other B-cell malignancies; and preclinical stage compounds comprise IMGN779 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. It also develops BT-062 for multiple myeloma; BAY 94-9343 for mesothelioma and ovarian cancers; SAR650984 that is in Phase II clinical trials for multiple myeloma; AMG 595, which is in Phase I clinical trials for glioblastoma; and SAR566658 Phase I clinical trials for CA6-positive solid tumors. In addition, the company develops AMG 172 that is in Phase I clinical trials for clear cell renal cell carcinoma; SAR408701, which is in Phase I clinical trials for CEACAM5-positive solid tumors; LOP628 that is in Phase I clinical trial for c-Kit-positive cancers; and PCA062, which is in Phase I clinical trial for P-cadherin-positive cancers. ImmunoGen, Inc. has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; Sanofi; Merck; and Takeda, as well as research agreement with CytomX Therapeutics to develop probody-drug conjugates against a specified number of cancers. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Analyst’s Recommendation on ConAgra Foods Incorporated (NYSE:CAG)

Analysts are weighing in on how ConAgra Foods Inc (NYSE:CAG), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 4 analysts, with 2 outperform and 7 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 13.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.52 a share, which would compare with $0.59 in the same quarter last year. They have a high estimate of $0.57 and a low estimate of $0.50. Revenue for the period is expected to total nearly $2.89B from $4.10B the year-ago period.

For the full year, 11.00 Wall Street analysts forecast this company would deliver earnings of 2.10 per share, with a high estimate of $2.34 and a low estimate of $2.06. It had reported earnings per share of $2.18 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $11.71B versus 15.83B in the preceding year.

The analysts project the company to maintain annual growth of around 6.98% percent over the next five years as compared to an average growth rate of 14.24% percent expected for its competitors in the same industry.

Among the 11 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CAG is $49.82 but some analysts are projecting the price to go as high as $53.00. If the optimistic analysts are correct, that represents a 11 percent upside potential from the recent closing price of $47.91. Some sell-side analysts, particularly the bearish ones, have called for $48.00 price targets on shares of ConAgra Foods Inc (NYSE:CAG).

In the last reported results, the company reported earnings of $0.59 per share, while analysts were calling for share earnings of $0.59. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

ConAgra Foods, Inc. operates as a food company primarily in North America. The company operates through three segments: Consumer Foods, Commercial Foods, and Private Brands. The Consumer Foods segment provides branded food products in various categories, such as meals, entrees, condiments, sides, snacks, and desserts to various retail channels, such as frozen, refrigerated, and shelf-stable temperature classes. This segments principal brands include ACT II, Banquet, Blue Bonnet, Chef Boyardee, DAVID, Egg Beaters, Healthy Choice, Hebrew National, Hunts, Marie Callenders, Orville Redenbachers, PAM, Peter Pan, Reddi-wip, Slim Jim, Snack Pack, Swiss Miss, Van Camps, and Wesson. The Commercial Foods segment offers frozen and sweet potato items, vegetable products, spices, bakery goods, and grain products to commercial, restaurants, foodservice, food manufacturing, and industrial customers under the Alexia, Lamb Weston, and Spicetec Flavors & Seasonings brands. The Private Brands segment offers private brand and customized food products in various retail channels, including bars, cereal, snacks, condiments, pasta, and retail bakery products. ConAgra Foods, Inc. was founded in 1919 and is headquartered in Omaha, Nebraska.

Analyst’s Recommendation on General Growth Properties Inc (NYSE:GGP)

Analysts are weighing in on how General Growth Properties Inc (NYSE:GGP), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 9 analysts, with 4 outperform and 5 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 18.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.36 a share, which would compare with $0.33 in the same quarter last year. They have a high estimate of $0.37 and a low estimate of $0.34. Revenue for the period is expected to total nearly $580.42M from $579.98M the year-ago period.

For the full year, 18.00 Wall Street analysts forecast this company would deliver earnings of 1.55 per share, with a high estimate of $1.58 and a low estimate of $1.49. It had reported earnings per share of $1.44 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $2.42B versus 2.40B in the preceding year.

The analysts project the company to maintain annual growth of around 7.10% percent over the next five years as compared to an average growth rate of 15.72% percent expected for its competitors in the same industry.

Among the 17 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for GGP is $32.35 but some analysts are projecting the price to go as high as $35.00. If the optimistic analysts are correct, that represents a 21 percent upside potential from the recent closing price of $29.00. Some sell-side analysts, particularly the bearish ones, have called for $29.00 price targets on shares of General Growth Properties Inc (NYSE:GGP).

In the last reported results, the company reported earnings of $0.33 per share, while analysts were calling for share earnings of $0.33. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.

Analyst’s Recommendation on Honeywell International Inc. (HON)

Analysts are weighing in on how Honeywell International Inc. (NYSE:HON), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.9. The stock is rated as buy by 10 analysts, with 7 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 19.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.64 a share, which would compare with $1.51 in the same quarter last year. They have a high estimate of $1.65 and a low estimate of $1.61. Revenue for the period is expected to total nearly $10.13B from $9.78B the year-ago period.

For the full year, 22.00 Wall Street analysts forecast this company would deliver earnings of 6.66 per share, with a high estimate of $6.70 and a low estimate of $6.55. It had reported earnings per share of $6.10 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $40.64B versus 38.58B in the preceding year.

The analysts project the company to maintain annual growth of around 8.56% percent over the next five years as compared to an average growth rate of 19.49% percent expected for its competitors in the same industry.

Among the 18 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for HON is $125.28 but some analysts are projecting the price to go as high as $135.00. If the optimistic analysts are correct, that represents a 15 percent upside potential from the recent closing price of $117.32. Some sell-side analysts, particularly the bearish ones, have called for $114.00 price targets on shares of Honeywell International Inc. (NYSE:HON).

In the last reported results, the company reported earnings of $1.51 per share, while analysts were calling for share earnings of $1.49. It was an earnings surprise of 1.30%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment offers aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors, as well as spare parts, and repair and maintenance services for the aftermarket. This segment also provides auxiliary power units; propulsion engines; environmental control, connectivity, electric power, flight safety, communication, navigation, radar, surveillance, and thermal systems; engine controls; aircraft lighting products, as well as wheels and brakes; advanced systems and instruments; and turbochargers, as well as management, technical, logistics, repair, and overhaul services to original equipment manufacturers in the air transport, regional, business, and general aviation aircraft; and automotive and truck manufacturers. The companys Automation and Control Solutions segment offers environmental and energy, and sensing and productivity solutions; security, and fire and industrial safety products; and building solutions and services for homes, commercial buildings, and industrial facilities. Its Performance Materials and Technologies segment provides catalysts and adsorbents; equipment and consulting services for the petroleum refining, gas processing, petrochemical, and other industries; and automation control, instrumentation, software, and services for the oil and gas, refining, pulp and paper, industrial power generation, chemicals and petrochemicals, biofuels, life sciences, metals, minerals, and mining industries. It also offers fluorocarbons, hydrofluoroolefins, caprolactam, resins, ammonium sulfate fertilizers, phenol, specialty films, waxes, additives, fibers, research chemicals and intermediates, and electronic materials and chemicals. The company was founded in 1920 and is based in Morris Plains, New Jersey.

Analyst’s Recommendation on Johnson Controls Incorporated (JCI)

Analysts are weighing in on how Johnson Controls Inc (NYSE:JCI), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.2. The stock is rated as buy by 5 analysts, with 5 outperform and 8 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 16.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.03 a share, which would compare with $0.91 in the same quarter last year. They have a high estimate of $1.06 and a low estimate of $1.00. Revenue for the period is expected to total nearly $9.63B from $9.61B the year-ago period.

For the full year, 18.00 Wall Street analysts forecast this company would deliver earnings of 3.91 per share, with a high estimate of $3.98 and a low estimate of $3.87. It had reported earnings per share of $3.42 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $37.30B versus 37.18B in the preceding year.

The analysts project the company to maintain annual growth of around 11.76% percent over the next five years as compared to an average growth rate of 11.94% percent expected for its competitors in the same industry.

Among the 14 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for JCI is $48.71 but some analysts are projecting the price to go as high as $54.00. If the optimistic analysts are correct, that represents a 20 percent upside potential from the recent closing price of $44.99. Some sell-side analysts, particularly the bearish ones, have called for $43.00 price targets on shares of Johnson Controls Inc (NYSE:JCI).

In the last reported results, the company reported earnings of $0.91 per share, while analysts were calling for share earnings of $0.91. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Johnson Controls, Inc. operates as a diversified technology and industrial company worldwide. Its Building Efficiency segment designs, produces, markets, and installs integrated heating, ventilating, and air conditioning systems, as well as building management systems, controls, and security and mechanical equipment. This segment also provides technical services, energy management consulting, residential air conditioning and heating systems, and industrial refrigeration products. The companys Automotive Experience segment designs and manufactures interior products and systems for passenger cars and light trucks, including vans, pick-up trucks, and sport/crossover utility vehicles serving original equipment manufacturers. This segment offers automotive seat metal structures and mechanisms, foam, trim, fabric, and seat systems; and instrument panels, floor consoles, and door panels. The companys Power Solutions segment produces lead-acid automotive batteries for passenger car, light truck, and utility vehicles, as well as offers advanced battery technologies to power start-stop, hybrid, and electric vehicles. It serves automotive original equipment manufacturers and the general vehicle battery aftermarket. The company was formerly known as Johnson Electric Service Company and changed its name to Johnson Controls, Inc. in 1974. Johnson Controls, Inc. was founded in 1885 and is headquartered in Milwaukee, Wisconsin.

Analyst’s Recommendation on NRG Energy Inc (NYSE:NRG)

Analysts are weighing in on how NRG Energy Inc (NYSE:NRG), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 5 analysts, with 4 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 6.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.26 a share, which would compare with $-0.06 in the same quarter last year. They have a high estimate of $1.13 and a low estimate of $-0.17. Revenue for the period is expected to total nearly $3.55B from $3.40B the year-ago period.

For the full year, 8.00 Wall Street analysts forecast this company would deliver earnings of 1.03 per share, with a high estimate of $1.65 and a low estimate of $0.40. It had reported earnings per share of $-0.34 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $13.83B versus 14.67B in the preceding year.

The analysts project the company to maintain annual growth of around 133.70% percent over the next five years as compared to an average growth rate of 6.59% percent expected for its competitors in the same industry.

Among the 14 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for NRG is $18.43 but some analysts are projecting the price to go as high as $27.00. If the optimistic analysts are correct, that represents a 86 percent upside potential from the recent closing price of $14.53. Some sell-side analysts, particularly the bearish ones, have called for $14.00 price targets on shares of NRG Energy Inc (NYSE:NRG).

In the last reported results, the company reported earnings of $-0.06 per share, while analysts were calling for share earnings of $-0.01. It was an earnings surprise of -500.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

NRG Energy, Inc., together with its subsidiaries, operates as a power company. The company provides electricity; system power, distributed generation, solar and wind products, backup generation, storage and distributed solar, demand response, energy efficiency, electric vehicle charging stations, and on-site energy solutions; carbon management and specialty services; and various energy services, such as operations, maintenance, technical, development, and asset management services. It owns and operates approximately 50,000 MWs of generation. The company also offers retail energy, rooftop solar, portable solar, and battery products home services; and various bundled products, which combine energy with protection products, energy efficiency, and renewable energy solutions, as well as offers installation and contract management services for residential solar customers. As of December 31, 2015, it served approximately 2.77 million recurring and 624,000 discrete customers. In addition, the company owns, operates, and develops solar and wind power projects; develops, constructs, and finances a range of solutions for utilities, schools, municipalities, and commercial markets; and trades in electric power, natural gas, and related commodity and financial products, including forwards, futures, options, and swaps. As of December 31, 2015, it operated 90 active fossil fuel and nuclear plants, 16 utility scale solar facilities, and 36 wind farms and multiple distributed solar facilities. Further, the company transacts in and trades fuel and transportation services; directly sells energy, services, and products and services to retail customers under the NRG, Reliant, and other names; and provides steam, hot water, and chilled water, as well as electricity to commercial businesses, universities, hospitals, and governmental units. NRG Energy, Inc. was founded in 1989 and is headquartered in Princeton, New Jersey.

Analyst’s Recommendation on Stone Energy Corp. (NYSE:SGY)

Analysts are weighing in on how Stone Energy Corporation (NYSE:SGY), might perform in the near term. Wall Street analysts have a unfavorable assessment of the stock, with a mean rating of 3.4. The stock is rated as buy by 0 analysts, with 0 outperform and 8 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 12.00 analysts offering adjusted EPS forecast have a consensus estimate of $-6.37 a share, which would compare with $-1.70 in the same quarter last year. They have a high estimate of $-1.50 and a low estimate of $-9.00. Revenue for the period is expected to total nearly $78.16M from $149.52M the year-ago period.

For the full year, 12.00 Wall Street analysts forecast this company would deliver earnings of -22.58 per share, with a high estimate of $-0.90 and a low estimate of $-31.30. It had reported earnings per share of $-5.20 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $331.98M versus 544.65M in the preceding year.

The analysts project the company to maintain annual growth of around -26.40% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 9 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for SGY is $10.14 but some analysts are projecting the price to go as high as $30.00. If the optimistic analysts are correct, that represents a 242 percent upside potential from the recent closing price of $8.78. Some sell-side analysts, particularly the bearish ones, have called for $3.00 price targets on shares of Stone Energy Corporation (NYSE:SGY).

In the last reported results, the company reported earnings of $-1.70 per share, while analysts were calling for share earnings of $-1.03. It was an earnings surprise of -65.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Stone Energy Corporation, an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and operation of oil and gas properties in the Gulf of Mexico. As of December 31, 2015, it had estimated proved oil and natural gas reserves of approximately 342 billion cubic feet of gas equivalent. The company was founded in 1993 and is headquartered in Lafayette, Louisiana.